Clinical trials: Influenza
Influenza Infection
Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants
The purpose of this study is to evaluate the immunogenicity and safety of TAK-850 administered subcutaneously as a single dose versus influenza HA vaccination in an exploratory manner.
- Trial name
- NCT02555618
- Testing
- TAK-850, Influenza HA vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.
- Trial name
- NCT01222403
- Testing
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine, Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine
- Where
- 23 sites in South Korea
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
- Trial name
- NCT00772889
- Testing
- Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01232868
- Testing
- trivalent Influenza vaccine (TIV)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
- Trial name
- NCT00764790
- Testing
- Fluarix, Fluzone
- Where
- 69 sites in United States, Hong Kong and 3 more
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of…
- Trial name
- MEDI8852 (NCT02603952)
- Testing
- Oseltamivir, MEDI8852
- Where
- 31 sites in United States, South Africa
- Volunteers
- 126 people
- Sponsor
- MedImmune LLC
Human Influenza, Respiratory Syncytial Virus Infections
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab.
- Conditions
- Human Influenza, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Enterovirus Infections
- Trial name
- SIMPLIFI (NCT04431050)
- Testing
- Point of care testing of respiratory viruses.
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2)…
- Trial name
- NCT05310084
- Testing
- BNT162b2, Seasonal Inactivated Influenza Vaccine
- Where
- 26 sites in Australia, New Zealand
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza
TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations
The Advisory Committee on Immunization Practices (ACIP)recommends that the flu vaccine be administered annually to all children aged 6 months to 18 years as well as women who are pregnant during the influenza season.
- Trial name
- NCT01146912
- Testing
- Text Message, automated call
- Where
- United States
- Volunteers
- 30,537 people
- Sponsor
- Columbia University
Herpes Zoster
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT01954251
- Testing
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Cancer
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV.
- Trial name
- NCT01205581
- Testing
- Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- St. Jude Children's Research Hospital
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Influenza A
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of…
- Trial name
- NCT02623322
- Testing
- MHAA4549A
- Where
- 80 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Genentech, Inc.
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV Infections, H1N1 Influenza Virus
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth
Children and people infected with HIV are particularly susceptible to influenza infections. This study testED the safety and effectiveness of a vaccine for the new H1N1 influenza virus in children and youth infected with HIV.
- Trial name
- NCT00992836
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, RNA Virus Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03739112
- Testing
- Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 12,794 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.
- Trial name
- NCT01310400
- Testing
- Inflexal V, Agrippal
- Where
- China
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Adult Stem Cell Hematopoetic Transplant
Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly different from adult stem cell…
- Trial name
- NCT01215734
- Testing
- High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt-Ingram Cancer Center